SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

EMA Validates Immunome’s Varegacestat Marketing Application

The EMA validated Immunome’s marketing application for varegacestat to treat adults with desmoid tumors, starting centralized review. The FDA has already accepted the NDA, with a PDUFA date of April 28, 2027.

IMNM

Related stories